EP2945628
Andrógenviðtakastillir ásamt abíraterón asetati og prednisóni til að meðhöndla krabbamein í blöðruhálskirtli
Status:
EP Einkaleyfi ógilt eftir andmæliEP appl. date:
9.1.2014EP published:
15.4.2020EP application number:
14701865.9
EP translation filed:
29.4.2020Grant published:
15.5.2020EPO information:
European Patent Register
Max expiry date:
8.1.2034Expiry date:
8.1.2022
Title:
ANDROGEN RECEPTOR MODULATOR IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE FOR TREATING PROSTATE CANCER
Timeline
Today
9.1.2014EP application
15.4.2020EP Publication
29.4.2020Translation submitted
15.5.2020Registration published
8.1.2022Expires
Owner
Name:
Aragon Pharmaceuticals, Inc.Address:
10990 Wilshire Blvd. Suite 300, Los Angeles, CA 90024, US
Inventor
Name:
CHEN, IsanAddress:
San Diego, California 92122, US
Name:
HAGER, Jeffrey H.Address:
San Diego, California 92130, US
Name:
MANEVAL, Edna ChowAddress:
San Diego, California 92130, US
Name:
HERBERT, Mark R.Address:
San Diego, California 92111, US
Name:
SMITH, Nicholas D.Address:
San Diego, California 92109, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201361752842 PDate:
15.1.2013Country:
US
Classification
Categories:
A61K 31/4439, A61K 45/06, A61P 35/00, A61P 35/04, A61P 5/28, A61P 17/14, A61K 47/10, A61K 47/34, A61K 47/44, A61K 9/48, A61K 38/09, A61K 9/00
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 15.12.2020
Expires: 8.1.2022
Payer: Árnason Faktor ehf.